MCID: PRS021
MIFTS: 43

Prostatic Adenoma

Categories: Cancer diseases, Reproductive diseases

Aliases & Classifications for Prostatic Adenoma

MalaCards integrated aliases for Prostatic Adenoma:

Name: Prostatic Adenoma 12 54 15 70
Prostatic Hyperplasia 44 70
Benign Prostatic Hyperplasia 70
Benign Adenoma of Prostate 12
Adenoma of Prostate 12
Adenoma - Prostate 12
Prostate Adenoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:2883
MeSH 44 D011470
NCIt 50 C4795
SNOMED-CT 67 21173002
UMLS 70 C0520477 C1704272 C2937421

Summaries for Prostatic Adenoma

Disease Ontology : 12 A male reproductive organ benign neoplasm that derives from glandular epithelial cells and that is located in the prostate.

MalaCards based summary : Prostatic Adenoma, also known as prostatic hyperplasia, is related to impotence and sexual disorder, and has symptoms including prostatism An important gene associated with Prostatic Adenoma is CDKN2B-AS1 (CDKN2B Antisense RNA 1), and among its related pathways/superpathways are Translation Non-genomic (rapid) action of Androgen Receptor and Nongenotropic Androgen signaling. The drugs Diclofenac and Silodosin have been mentioned in the context of this disorder. Affiliated tissues include prostate, smooth muscle and bone.

Related Diseases for Prostatic Adenoma

Diseases related to Prostatic Adenoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 327)
# Related Disease Score Top Affiliating Genes
1 impotence 31.4 SRD5A1 SHBG PRL KLK3
2 sexual disorder 31.0 SHBG PRL KLK3 AR
3 suppression of tumorigenicity 12 30.6 SERPINA3 KLK3 AR
4 prostatitis 30.6 SERPINA3 PRL KLK3 ACP3
5 prostatic hypertrophy 30.5 SRD5A1 SERPINA3 KLK3 AR ACP3
6 alopecia, androgenetic, 1 30.4 SRD5A1 SHBG AR
7 varicocele 30.3 SHBG PRL AR
8 prostatic hyperplasia, benign 30.3 SRD5A1 SERPINA3 KLK3 AR ACP3
9 alopecia 30.3 SRD5A1 SHBG PRL AR
10 estrogen excess 30.1 SHBG PRL
11 gynecomastia 30.1 SRD5A1 SHBG PRL KLK3 AR
12 prostatic acinar adenocarcinoma 30.1 KLK3 AR
13 androgenic alopecia 30.0 SRD5A1 SHBG PRL KLK3 AR
14 prostate disease 29.6 SRD5A1 SERPINA3 KLK3 CDKN2B-AS1 AR ACP3
15 thyroid gland disease 29.6 SHBG SERPINA3 PRL
16 hypogonadism 29.6 SHBG PRL AR
17 hyperandrogenism 29.5 SRD5A1 SHBG PRL AR
18 acne 29.5 SRD5A1 SHBG PRL AR
19 polycystic ovary syndrome 29.5 SRD5A1 SHBG PRL AR
20 cryptorchidism, unilateral or bilateral 29.5 SRD5A1 SHBG PRL AR
21 acute myocardial infarction 29.5 UCA1 SERPINA3 CDKN2B-AS1
22 breast disease 29.4 SHBG SERPINA3 PRL KLK3
23 prostate cancer 28.1 UCA1 SRD5A1 SHBG SERPINA3 MXI1 KLK3
24 adenoma 11.2
25 benign prostate phyllodes tumor 11.1
26 pure autonomic failure 10.6
27 overgrowth syndrome 10.6
28 urinary tract obstruction 10.6
29 body mass index quantitative trait locus 1 10.5
30 adenocarcinoma 10.5
31 aging 10.5
32 bladder cancer 10.4
33 neurogenic bladder 10.4
34 47,xyy 10.4
35 48,xyyy 10.4
36 b-cell lymphoma 10.4
37 multinucleated neurons, anhydramnios, renal dysplasia, cerebellar hypoplasia, and hydranencephaly 10.4
38 insulin-like growth factor i 10.3
39 pachyonychia congenita 3 10.3
40 infant gynecomastia 10.3
41 hyperinsulinism 10.3
42 cystitis 10.3
43 pik3ca-related overgrowth syndrome 10.3
44 pyelonephritis 10.3
45 chronic kidney disease 10.3
46 syncope 10.3
47 penis agenesis 10.3 SRD5A1 AR
48 prostate adenoid cystic carcinoma 10.3 KLK3 AR
49 prostate leiomyoma 10.2 KLK3 AR
50 proteasome-associated autoinflammatory syndrome 1 10.2

Graphical network of the top 20 diseases related to Prostatic Adenoma:



Diseases related to Prostatic Adenoma

Symptoms & Phenotypes for Prostatic Adenoma

UMLS symptoms related to Prostatic Adenoma:


prostatism

Drugs & Therapeutics for Prostatic Adenoma

Drugs for Prostatic Adenoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
2
Silodosin Approved Phase 4 160970-54-7
3
Saw palmetto Approved, Experimental, Investigational Phase 4
4
Testosterone Approved, Investigational Phase 4 58-22-0 6013
5
Sodium citrate Approved, Investigational Phase 4 68-04-2
6
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
7
carbamide peroxide Approved Phase 4 124-43-6
8
Methyltestosterone Approved Phase 4 58-18-4 6010
9
Testosterone undecanoate Approved, Investigational Phase 4 5949-44-0
10
Testosterone enanthate Approved Phase 4 315-37-7 9416
11
Ciprofloxacin Approved, Investigational Phase 4 85721-33-1 2764
12
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
13
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
14
Dihydrotachysterol Approved Phase 4 67-96-9 5311071 5281010
15
Mivacurium Approved Phase 4 106791-40-6, 133814-19-4 5281042
16
Atracurium Approved, Experimental, Investigational Phase 4 64228-79-1 47319
17
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
18
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
19
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
20
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
21
Mirabegron Approved Phase 4 223673-61-8 9865528
22
Methoxyflurane Approved, Investigational, Vet_approved Phase 4 76-38-0 4116
23
Dutasteride Approved, Investigational Phase 4 164656-23-9 6918296 152945
24
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
25
Aspartic acid Approved, Nutraceutical Phase 4 56-84-8 5960
26
Dihydrotestosterone Illicit, Investigational Phase 4 521-18-6 10635
27
Naftopidil Investigational Phase 4 57149-07-2
28 Androgens Phase 4
29 calcium channel blockers Phase 4
30 Calcium, Dietary Phase 4
31 5-alpha Reductase Inhibitors Phase 4
32 Cholinergic Agents Phase 4
33 Saw palmetto extract Phase 4
34 Anesthetics, Local Phase 4
35 Solifenacin succinate Phase 4 242478-38-2
36 Muscarinic Antagonists Phase 4
37 Cholinergic Antagonists Phase 4
38 Anti-Infective Agents Phase 4
39 Citrate Phase 4
40 Sildenafil Citrate Phase 4 171599-83-0
41 Mitogens Phase 4
42 Antibiotics, Antitubercular Phase 4
43 Anti-Bacterial Agents Phase 4
44
Bilirubin Phase 4 635-65-4 5280352
45 N-Methylaspartate Phase 4
46 Testosterone 17 beta-cypionate Phase 4
47 Tolterodine tartrate Phase 4 124937-52-6
48 Endothelial Growth Factors Phase 4
49 Anti-Arrhythmia Agents Phase 4
50 Sodium Channel Blockers Phase 4

Interventional clinical trials:

(show top 50) (show all 530)
# Name Status NCT ID Phase Drugs
1 Clinical Pilot Trial on the Influence of a Saw Palmetto Berry Preparation on Sexual Functions in Patients With Benign Prostatic Hyperplasia Unknown status NCT01021267 Phase 4 Saw palmetto berry extract
2 Comparison of Medical and Surgical Treatments of Benign Prostate Hyperplasia in Patients Who Have Low Grade Non Muscle Invasive Bladder Cancer for Tumour Recurrence and Progression Unknown status NCT02443844 Phase 4 Tamsulosin
3 Prostatic Artery Embolization Versus 532 nm Green Light Laser Photoselective Vaporization of the Prostate for Treating Catheter-Dependent Patients With Benign Prostatic Hyperplasia: A Randomized Controlled Clinical Study Unknown status NCT02006303 Phase 4
4 Post-Marketing Study Using PROLIEVE® for the Treatment of Benign Prostatic Hyperplasia (BPH) Unknown status NCT02021032 Phase 4
5 Kinetics of the Finasteride Prostate Induced Apoptosis Unknown status NCT00130767 Phase 4 finasteride
6 Prospective Non-randomized Trial Comparing Holmium Laser Enucleation of the Prostate Versus Greenlight Laser Photoselective Vaporization of the Prostate in Treating Benign Prostate Hyperplasia in Patients With Bleeding Tendency Unknown status NCT02293759 Phase 4
7 Switch Study: Are There Any Measurable Differences When Switching Patients on Finasteride Therapy to Dutasteride? Unknown status NCT00690950 Phase 4 Dutasteride
8 Evaluation of Solifenacin in the Treatment of OAB Symptoms in Patients Who Have Successfully Undergone GreenLight Photoselective Vaporization of the Prostate (PVP)for the Treatment of Clinically Significant Benign Prostate Hyperplasia (BPH) Unknown status NCT00826527 Phase 4 Solifenacin PO
9 Low Dose, Low Concentration Different Baricity Bupivacaine for Transuretral Prostatectomy. Unknown status NCT01861041 Phase 4 Heavy Bupivacaine;Isobaric Bupivacaine
10 A Multicenter, Randomized, Double-blind, Clinical Study to Investigate the Efficacy and Safety of Treatment With Tamsulosin 0.2mg Mono and Tamsulosin 0.2mg, Finasteride 5mg Combination Therapy in Patients With LUTS/BPH Unknown status NCT01736033 Phase 4 Tamsulosin;Finasteride;Placebo
11 Ejaculatory Sparing vs. Non-ejaculatory Sparing GreenLightTM Laser Photoselective Vaporization of the Prostate (PVP): A Randomized Double Blind Sexual and Urodynamic Assessment Unknown status NCT02749604 Phase 4
12 Comparation the Effect of C-LMA and I-gel in Regurgitation and Postoperative Complications Unknown status NCT01876836 Phase 4
13 The Effect of Preemptive Analgesia On The Comfort Of Patient and Doctor, in Cystoscopy Unknown status NCT03831321 Phase 4 Diclofenac Sodium;Lubricant Gel
14 Effectiveness and Safety of Silodosin in the Treatment of LUTS in Patients With Benign Prostatic Hyperplasia: a European Phase IV Clinical Study. The Silodosin in Real-life Evaluation Study Completed NCT01757769 Phase 4 Silodosin
15 A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia Completed NCT01259531 Phase 4 Silodosin
16 Green Light Laser (XPS) Photoselective Vaporization of the Prostate (PVP) Versus Bipolar Transurethral Vaporization (B.TUVP) of the Prostate for Treatment of Small to Moderate Sized Benign Prostate Hyperplasia: A Randomized Study Completed NCT02283684 Phase 4
17 Randomized Study Comparing Holmium Laser Enucleation of the Prostate (HOLEP) Versus Greenlight (XPS) Laser Photoselective Vapo-Enucleation of Prostate(PVEP) in the Management of Infravesical Obstruction Secondary to BPH Completed NCT01494337 Phase 4
18 Evaluation of the Effects of Monopolar Transurethral Resection Versus Bipolar Transurethral Resection and Holmium Laser Enucleation of the Prostate on Urinary and Sexual Function; a Prospective Comparative Study. Completed NCT01810068 Phase 4
19 A Prospective Clinical Study for GreenLight HPS in the Treatment of Obstructive Benign Prostatic Hyperplasia (BPH) Completed NCT00465101 Phase 4
20 A Randomized, Open-label, Parallel-group Study, to Assess the Pharmocodynamic Effect on Dihydrotestosterone Regulated Gene Expression, Longitudinally and in a Dose Dependent Manner, of 0.5mg and 3.5mg Dutasteride Administered Orally Once Daily, for One Year in Men With Symptomatic Benign Prostatic Hyperplasia and During a Two Month Period Between Baseline and Radical Prostatectomy in Men With Biopsy-proven, Clinically Localized Prostate Cancer Completed NCT00375765 Phase 4 Dutasteride
21 A Prospective Evaluation of the GreenLight Model 120 Laser System for the Treatment of Benign Prostatic Hyperplasia Completed NCT00364585 Phase 4
22 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL OD 10mg), Open, 24-week Study Completed NCT00486785 Phase 4 Alfuzosin
23 An Open-Label Randomized Phase 4 Study of Greenlight XPS Laser Versus BiVAP Saline Vaporization of the Prostate in Men With Symptomatic Benign Prostatic Hyperplasia Completed NCT01500057 Phase 4
24 Benign Prostatic Hyperplasia and Ischemic Heart DIsease Completed NCT03856242 Phase 4 Tamsulosin Oral Capsule
25 Effectiveness of Testosterone Replacement Therapy (TRT) on Prostatic Gland in Hypogonadal Patients Affected by Benign Prostatic Hyperplasia (BPH) and Metabolic Syndrome (MetS). Florence-PROTEST Completed NCT02366975 Phase 4 Testosterone gel 2%
26 The Effects of Systemic Alfuzosin and Tamsulosin Hydrochloride on Choroidal Thickness and Pupil Diameter Sizes in Cases With Benign Prostatic Hyperplasia Completed NCT03144596 Phase 4 Alfuzosin Hydrochloride 10 MG;Tamsulosin Hydrochloride 0.4 MG
27 A Randomized, Double-blind, Placebo-controlled Study to Assess the Effect of Tamsulosin OCAS 0.4 mg Tablets, Once Daily on Nocturia, Compared to Placebo, in Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT00379067 Phase 4 Tamsulosin OCAS;Placebo
28 Study of the Outcome of Patients With Lower Urinary Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Alfuzosin 10 mg Once Daily for 3 Months in China Completed NCT00280605 Phase 4 Alfuzosin
29 A Multicenter, Randomized, Parallel Group, Double-blind, Placebo-controlled Flexible Dose Study With and Open-label Extension to Assess the Efficacy and Safety of Viagra (Sildenafil Citrate) in the Treatment of Men With Erectile Dysfunction (ED) and Concomitant Lower Urinary Tract Symptoms (LUTS) Associated With Benign Prostatic Hyperplasia (BPH) in the United States Completed NCT00143221 Phase 4 Viagra;Placebo
30 A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH) Completed NCT02757768 Phase 4 Mirabegron;Placebo;Tamsulosin Hydrochloride
31 Sexuality And Management of Benign Prostatic Hyperplasia With Alfuzosin 10mg Once Daily (XATRAL 10mg OD), Open, 24-week Study. Completed NCT00401661 Phase 4 Alfuzosin
32 An Eleven-Week, Open-Label, Randomized, Multicenter, Parallel-Design, Placebo Lead-in Study of FLOMAX® Capsules, 0.4 mg Daily Versus HYTRIN® Capsules, 5 mg (With Titration) Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244255 Phase 4 FLOMAX® capsules;Ascending doses of HYTRIN® capsules
33 A Forty-Five Day, Open-label Study of the Symptomatic Relief Effects of FLOMAX® Capsules 0.4 mg Daily in Patients With the Signs and Symptoms of Benign Prostatic Hyperplasia Completed NCT02244242 Phase 4 Tamsulosin hydrochloride
34 MICTUS (Multicentre Investigation to Characterise the Effect of Tamsulosin on Urinary Symptoms): A Multicentre, Double-blind, Randomised, Parallel Group Study, Aimed at Characterising the Effect of Tamsulosin, an Uroselective α1- Receptor Blocking Agent, on the Urological Symptoms and Their Impact on General Health Status and Quality of Life in Outpatients Affected by Symptomatic Benign Prostatic Hyperplasia: Comparison With Finasteride. Completed NCT02244229 Phase 4 Tamsulosin;Finasteride;Placebo
35 BLADDER (BPH, LUTS And Detrusor: Dual Effect Research) Study: A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study, Aimed at Characterising the Effect of Tamsulosin on Lower Urinary Tract Symptoms (LUTS) and Detrusor Motor Activity in Patients Affected by Benign Prostatic Hyperplasia (BPH) and Storage Urinary Symptoms Completed NCT02245490 Phase 4 Tamsulosin HCl controlled release capsules;Matching placebo capsule
36 A Randomized, Double-blind, Double-dummy, Placebo-controlled, Parallel Design Clinical Trial to Evaluate the Efficacy and Safety of Naftopidil in Male Patients With Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia Completed NCT01922375 Phase 4 Naftopidil
37 PERMIXON® 160 mg Hard Capsule Versus Placebo in the Treatment of Symptomatic Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia Completed NCT02121613 Phase 4 Permixon® 160 mg;Tamsulosine LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine LP
38 A Multi-center, Prospective, Open-label, Single-arm, 12-weeks, Phase IV Trial to Evaluate the Efficacy and Safety of Silodosin on Nocturia for Patients With Benign Prostatic Hyperplasia Completed NCT02106182 Phase 4 Silodosin
39 Comparison Between Alpha Blocker Monotherapy and 5-alpha-reductase Inhibitor Monotherapy Following Combination Therapy in Benign Prostatic Hyperplasia Completed NCT01301599 Phase 4 combination therapy;alpha blocker monotherapy;5 alpha reductase inhibitor monotherapy
40 A Phase 4, Double-blind, Randomized, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Mirabegron in Japanese and Korean Male Patients With Overactive Bladder Under Treatment With the α-Blocker Tamsulosin for Benign Prostatic Hyperplasia Completed NCT02656173 Phase 4 Mirabegron;Placebo;Tamsulosin
41 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study of Solifenacin Succinate as Add-on Therapy for Overactive Bladder (OAB) Symptoms in Men Treated for Benign Prostatic Hyperplasia (BPH) With Tamsulosin Hydrochloride Completed NCT00771394 Phase 4 Tamsulosin hydrochloride;Solifenacin succinate
42 Efficacy and Safety of Naftopidil in Patient With Neurogenic Lower Urinary Tract Dysfunction Not Caused by Benign Prostatic Hyperplasia Completed NCT02034604 Phase 4 Naftofidil;Tamsulosin
43 The Effect of KTP (Potassium-titanyl-phosphate) Green Light Prostatectomy (180W) Compared With Open Prostatectomy When Treating Benign Prostatic Hyperplasia, a Prospective Randomized Study Completed NCT02072499 Phase 4
44 Efficacy of Silodosin in the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH) Completed NCT04107896 Phase 4 Silodosin;Tamsulosin
45 The Long Term Effects of Alfuzosin (Xatral XL) in LUTS/BPH Patients: Evaluation of Symptom-specific Goal Achievement According to Symptom Improvement, Bladder Outlet Obstruction Grade and Bladder Contractility Completed NCT00836823 Phase 4 Alfuzosin
46 Effect of Dutasteride on Bladder Wall Hypertrophy in Patients With Benign Prostatic Obstruction: A 24-Week Open-Label, Single-Arm Pilot Study Completed NCT00827814 Phase 4 Dutasteride
47 A Post-Marketing Clinical Study of LY450190 (Combined With Alpha1 Blocker Treatment) Completed NCT02431754 Phase 4 Tadalafil;Placebo;Alpha1 Blocker
48 Exploratory Study of L.S.E.S.r. (PERMIXON® 160 mg Hard Capsule) Versus Tamsulosine LP Activity on Inflammation Biomarkers in the Treatment of Urinary Symptoms Related to BPH; a Multinational, Multicentric, Randomised, Double Blind Parallel-group Prospective Study Completed NCT01604811 Phase 4 Permixon® 160 mg;Tamsulosine Arrow LP;Placebo matching Permixon® 160 mg;Placebo matching Tamsulosine Arrow LP
49 Dutasteride (0.5mg) Once Daily for One Year and Tamsulosin (0.4mg) Once Daily for 3 Months, Followed by Counseling on Flex Dose Tamsulosin as Needed on Improvement of Symptoms and Outcome in Men With Moderate to Severe Symptomatic BPH Completed NCT00701779 Phase 4 Tamsulosin
50 Assessment of Prostatic Tissue Concentration of Ertapenem After a Pre-operative Administration Completed NCT02041767 Phase 4 Ertapenem

Search NIH Clinical Center for Prostatic Adenoma

Inferred drug relations via UMLS 70 / NDF-RT 51 :


alfuzosin
Doxazosin
Doxazosin Mesylate
Dutasteride
Finasteride
Leuprolide
Leuprolide Acetate
Prazosin
Prazosin hydrochloride
Saw palmetto extract
silodosin
tamsulosin
Tamsulosin hydrochloride
Terazosin
terazosin hydrochloride

Cochrane evidence based reviews: prostatic hyperplasia

Genetic Tests for Prostatic Adenoma

Anatomical Context for Prostatic Adenoma

The Foundational Model of Anatomy Ontology organs/tissues related to Prostatic Adenoma:

19
Prostate

MalaCards organs/tissues related to Prostatic Adenoma:

40
Prostate, Smooth Muscle, Bone, Endothelial, Kidney, Liver, Heart

Publications for Prostatic Adenoma

Articles related to Prostatic Adenoma:

(show top 50) (show all 15356)
# Title Authors PMID Year
1
[Efficacy and safety of combined treatment of prostatic adenoma with 5-alpha reductase and alpha-adrenoblockers]. 61 54
20169718 2009
2
[Green light laser efficacy in patients with prostatic hyperplasia treatment with 5-alpha reductase inhibitors]. 61 54
19925759 2009
3
[The experience in dutasteride use before transurethral prostatic resection for large adenoma]. 61 54
19054996 2008
4
Serum sex steroids, gonadotrophins and sex hormone-binding globulin in prostatic hyperplasia. 54 61
18500180 2008
5
Expression of estrogen receptor-B ( ER-B ) in bengin and malignant prostatic epithelial cells and its correlation with the clinico-pathological features. 54 61
19672287 2007
6
[Dutasteride--an inhibitor of 5alpha-reductase of type I and II--in the treatment of patients with prostatic adenoma. What is the latest news?]. 61 54
18652016 2007
7
[Treatment of prostatic adenoma patients with inhibitor of 5-alpha-reductase of type I and II avodart (dutasteride)]. 54 61
17315721 2006
8
Impact of prostate-specific antigen level and prostate volume as predictors of efficacy in photoselective vaporization prostatectomy: analysis and results of an ongoing prospective multicentre study at 3 years. 54 61
16686717 2006
9
Relationship among serum testosterone, sexual function, and response to treatment in men receiving dutasteride for benign prostatic hyperplasia. 54 61
16434455 2006
10
[Studies on sex hormone-binding globulin in the prostate]. 54 61
15267211 2004
11
Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia. 61 54
15072886 2004
12
[5-alpha reductase inhibitors or alpha blockers? The combination brakes best prostatic hyperplasia]. 54 61
12494605 2002
13
Impact of constitutional genetic variation in androgen/oestrogen-regulating genes on age-related changes in human prostate. 61 54
12370109 2002
14
[Five-year experience in treating patients with prostatic hyperplasia patients with permixone (Serenoa repens "Pierre Fabre Medicament)]. 61 54
11877967 2002
15
Inflammation and glandular proliferation in hyperplastic prostates: association with prostate specific antigen value. 61 54
12197626 2001
16
Novel expression patterns of the myc/max/mad transcription factor network in developing murine prostate gland. 61 54
11490301 2001
17
Predictive value of total and percent free prostate specific antigen in high grade prostatic intraepithelial neoplasia lesions: results of the Tyrol Prostate Specific Antigen Screening Project. 54 61
11257656 2001
18
[Differential diagnostic value of prostate-specific antigen in prostatic hyperplasia]. 54 61
11490716 2001
19
Effect of two years of growth hormone and insulin-like growth factor-I suppression on prostate diseases in acromegalic patients. 54 61
11061535 2000
20
Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride. 61 54
10386468 1999
21
Significance of examination of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hyperplasia and prostate cancer. 61 54
9406003 1997
22
Coregulatory effects of epidermal growth factor, dihydrotestosterone, and prolactin on benign human prostatic hyperplasia tissue culture proliferation. 61 54
9018335 1997
23
Management of urinary incontinence in the elderly. 61 54
9142509 1997
24
[Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia]. 61 54
8928344 1996
25
Effect of digital rectal examination on plasma prostate-specific antigen (PSA). 54 61
8836791 1996
26
Age-dependent expression of the androgen receptor gene in the prostate and its implication in glandular differentiation and hyperplasia. 61 54
8934871 1996
27
The efficacy of finasteride in the treatment of symptomatic benign prostatic hyperplasia. 61 54
8851481 1995
28
Prostate-specific antigen (PSA) and cancer-associated serum antigen (CASA) in distinguishing benign and malignant prostate disease. 54 61
8750649 1995
29
[Status of PSA determination for early detection of prostate carcinoma]. 54 61
7541925 1995
30
[Organ culture of human tissue as study model of hormonal and pharmacological regulation of benign prostatic hyperplasia and of prostatic cancer]. 61 54
7537011 1995
31
Relationship between prostate-specific antigen, prostate volume, retention volume and age in benign prostatic hypertrophy (BPH). 54 61
8725044 1995
32
5 alpha-reductase inhibitors and prostatic disease. 61 54
7522999 1994
33
Predicted and actual change in serum PSA following prostatectomy for BPH. 61 54
7512298 1994
34
Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin. 54 61
7691441 1993
35
[Effect of rectal examination in patients with prostatic adenoma on concentration of prostatic specific antigen (PSA) in plasma]. 61 54
7526558 1993
36
Evaluation of PAP and PSA gene expression in prostatic hyperplasia and prostatic carcinoma using northern-blot analyses, in situ hybridization and immunohistochemical stainings with monoclonal and bispecific antibodies. 54 61
7691762 1993
37
[Reliability and use of prostate-specific antigen in the management of patients with prostatic cancer]. 61 54
7688112 1993
38
Prostate-specific antigen in the follow-up of prostatic adenocarcinoma treated with external beam radiation. 54 61
1708923 1991
39
Experience with prostate-specific antigen in prostatic carcinoma. 54 61
1718923 1991
40
[5-alpha reductase inhibitor in prostatic adenoma?]. 61 54
1705307 1990
41
Plasma sex hormone binding globulin in patients with prostatic carcinoma. 61 54
1695120 1990
42
Time-resolved immunofluorometric assay of human prostate-specific antigen. 61 54
1688748 1990
43
Progenitors in prostate development and disease. 61
33529704 2021
44
A Proof-of-Concept Study on the Use of Prostate Artery Embolization Before Definitive Radiation Therapy in Prostate Cancer. 61
33748542 2021
45
Prospective evaluation of the association between varicocele and benign prostatic hyperplasia in men over 40 years of age. 61
33586806 2021
46
Alfuzosin and Its Effect on Ejaculatory Dysfunction: A Systematic Review. 61
32009306 2021
47
Male Voiding Behavior: Insight from 19,824 At-Home Uroflow Profiles. 61
33259269 2021
48
Bipolar radiofrequency thermotherapy treatment of the prostate in urinary catheter-dependent men. 61
32989897 2021
49
Improving Cone-Beam CT Angiography for Prostatic Artery Embolization: Is a Low-Dose Protocol Equivalent to the Standard? 61
33558125 2021
50
Development of a naftopidil-chitosan-based fumaric acid solid dispersion to improve the dissolution rate and stability of naftopidil. 61
33607140 2021

Variations for Prostatic Adenoma

Expression for Prostatic Adenoma

Search GEO for disease gene expression data for Prostatic Adenoma.

Pathways for Prostatic Adenoma

Pathways related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.45 SRD5A1 KLK3 AR
2 9.88 SHBG AR

GO Terms for Prostatic Adenoma

Biological processes related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of systemic arterial blood pressure GO:0003073 8.96 KLK3 AR
2 cellular response to testosterone stimulus GO:0071394 8.62 SRD5A1 AR

Molecular functions related to Prostatic Adenoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.96 SHBG AR
2 androgen binding GO:0005497 8.62 SHBG AR

Sources for Prostatic Adenoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....